Achilles Therapeutics
London
United Kingdom
About Achilles Therapeutics
Achilles intends to develop next-generation personalized vaccines and adoptive T cell therapies for metastatic cancer by targeting truncal tumor neoantigens. The company is based on research at University College London, Cancer Research UK (CRUK) and the Francis Crick Institute.YEAR FOUNDED:
2016
LEADERSHIP:
Scientific Founder: Charles Swanton
CEO: Chris Ashton
49 articles with Achilles Therapeutics
-
Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio's pediatric methylmalonic acidemia study is back up and running and another look at Roche's TIGIT flop.
-
Researchers at Yale University published research in Molecular Biology and Evolution describing a new molecular analysis approach to quantify DNA changes that contribute to cancer growth.
-
Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
5/10/2022
Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2022, and recent business highlights.
-
Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma
5/9/2022
Achilles Therapeutics plc (NASDAQ: ACHL), today announced that the first patient has been dosed with personalized clonal neoantigen-reactive T cells, or cNeT, manufactured with the Company’s higher-dose VELOS™ Process 2 in the ongoing Phase I/IIa CHIRON clinical trial for the treatment of advanced non-small cell lung cancer (NSCLC).
-
BioSpace Movers & Shakers, May 6
5/6/2022
Biopharma and life sciences companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers. -
Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors
5/4/2022
Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of Bernhard Ehmer, MD, to the Board as a Non-Executive Director.
-
Achilles Therapeutics to Present at Upcoming Conferences
5/3/2022
Achilles Therapeutics plc today announced that the Company will be taking part in the following conferences in May.
-
Australia’s Chimeric Therapeutics has partnered with WuXi ATU on two autologous CAR T-cell therapies for solid tumors. Switzerland-based CDR-Life closed a $76 million Series A.
-
Achilles Therapeutics Announces Manufacturing Expansion in the UK and Partnership for Manufacturing in the US
4/12/2022
Achilles Therapeutics plc, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, announced clinical manufacturing expansion in the United Kingdom and the United States.
-
Achilles Therapeutics to Present at Upcoming Conferences - Apr 05, 2022
4/5/2022
Achilles Therapeutics plc, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, announced that management will be taking part in the following conferences in April.
-
Achilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting
4/4/2022
Achilles Therapeutics plc announced that the Company will host a key opinion leader webcast to discuss the importance and unique utility of the TRACERx study in validating the identification of clonal neoantigens as targets for personalized T cell therapies and to highlight selections from the 31 posters and presentations on the TRACERx study presented at the 2022 American Association for Cancer Research Annual Meeting.
-
Achilles Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
3/8/2022
Achilles Therapeutics plc, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, announced its participation in the 32nd Annual Oppenheimer Healthcare Conference taking place virtually March 15 - 17, 2022.
-
Achilles Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Business Highlights
3/1/2022
Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its financial results for the fourth quarter and year-ended December 31, 2021, and recent business highlights.
-
BioSpace Movers & Shakers, Feb. 11
2/11/2022
Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers. -
Achilles Therapeutics Strengthens Scientific Advisory Board with Appointment of Alena Gros, Ph.D. and Ben Creelan, M.D.
2/7/2022
Achilles Therapeutics plc today announced the appointment of Alena Gros, Ph.D. and Ben Creelan, M.D. to its Scientific Advisory Board (SAB).
-
Looking at long-term growth, Michael said that will be driven by numerous differentiated assets across each of Abbvie’s core areas.
-
Achilles Therapeutics Provides Business Update and Outlook for 2022
1/13/2022
Achilles Therapeutics plc today announces a business update and reflects on recent progress with its pioneering, personalized T cell therapy programs targeting clonal neoantigens known as cNeT.
-
Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference
12/21/2021
Achilles Therapeutics plc announced that Iraj Ali, Chief Executive Officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022, at 8:15 a.m. ET.
-
Achilles Therapeutics Added to the NASDAQ Biotechnology Index
12/20/2021
Achilles Therapeutics plc announced that the Company has been added to the NASDAQ Biotech Index, effective prior to market open, Monday, December 20, 2021.
-
Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal Neoantigens
12/9/2021
Achilles Therapeutics plc today presented positive data at the ESMO Immuno-Oncology Congress 2021.